Skip to content

Author

Xi-Rui Lin

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Association of trilaciclib use with hematologic outcomes during perioperative immunochemotherapy in resectable esophageal squamous cell carcinoma: a prospective observational cohort study

Background Perioperative immunochemotherapy is a key treatment strategy for resectable esophageal squamous cell carcinoma (ESCC), but chemotherapy-induced myelosuppression (CIM) may compromise treatment delivery. Trilaciclib, a transiently acting, reversible cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has shown mye...

Chao-Quan He, Xi-Rui Lin, Hai-Jie Xu et al. · 0 citations
Open access Sep 2026

Not all major pathological responses are equal: prognostic heterogeneity and risk stratification after neoadjuvant chemoimmunotherapy in resectable NSCLC

Background Major pathological response (MPR) is a widely used efficacy endpoint for neoadjuvant chemoimmunotherapy (NCIT) in resectable non-small cell lung cancer (NSCLC). However, whether MPR without pathological complete response (pCR) represents a prognostically homogeneous population remains unclear, and optimal po...

Jiong Lin, Hai-Jie Xu, Ji-Ming Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.